Prof.Dr.Cumali Aktolun’un Kitapları
1) NUCLEAR ONCOLOGY (Lippincott Williams Wilkins, 2014-2015, USA)
Kitabın başyazarları; Prof.Dr.Cumali Aktolun ve USA Cornell Üniversitesi Tıp Fakültesi New York Presbyterian Hastanesinden Prof.Stanley J Goldsmith’tir. Başyazarlığa ilaveten, kitabın, tiroid kanseri ile ilgili bölümünü Prof.Dr.Cumali Aktolun ve birlikte çalıştığı ekibi yazmıştır. Tiroid kanserleri, nöroendokrin tümörler, endokrinolojik tümörler de dahil bir çok tümörde radyoaktif maddeleri kullanarak yapılan tanı ve tedavi tekniklerini ve güncel bilgileri kapsayan bu kitap, referans bir eser olma özelliği taşımaktadır. PET/CT, PET/MR, SPECT/CT, SPECT, sentinel lenf nod, intraoperatif ileri tıbbi görüntüleme ve deneysel fotoakustik görüntüleme teknikleri ile monoklonal antikorları, reseptör analogları ve mikroküre uygulamaları da dahil en gelişmiş, yeni terapötik yöntemleri ayrıntılarıyla veren kitapta geleceğe dönük projeksiyonlar da sunulmaktadır.
Kitaba, Nükleer Tıp’ın en saygın üyelerinden biri olan Profesör Heinrich Schelbert tarafından bir önsöz yazılmıştır. Hazırlık yazım işlemleri 2009’dan beri süren bu kitap, bütün dünyada Ekim 2014’te satışa sunulmuştur. (www.amazon.com). Kitap, 43 bölümden oluşmaktadır. Atlas boy olarak basılan ve tamamı renkli olan bu kitap 750 sayfadır.
2) NUCLEAR MEDICINE THERAPY: Principles and Clinical Applications (Springer, 2012-2013, USA)
Prof.Dr.Cumali Aktolun, Cornell Universitesi öğretim üyesi Prof.Dr.Stanley J Goldsmith ile birlikte, bu kitabın başyazarıdır. Bu kitap, Prof.Dr.Cumali Aktolun’un Amerika Birleşik Devletlerinde yayınlanmış ve tüm dünyada satılan 2. kitabıdır. Kitap, tiroid hastalıkları ve nöroendokrin tümörler de dahil Endokrinoloji, Onkoloji ve Romatoloji branşlarında Nükleer Tıp teknikleri kullanılarak yapılan tedavi yöntemlerini anlatmaktadır.
Kitabın başyazarları; Prof.Dr.Cumali Aktolun ve USA Cornell Üniversitesi Tıp Fakültesi New York Presbyterian Hastanesinden Prof.Stanley J Goldsmith’tir. Kitap İngilizce olarak yazılmıştır. Başyazarlığa ilaveten, kitabın, tiroid hastalıkları ile ilgili bölüm, Prof.Dr.Cumali Aktolun ve birlikte çalıştığı ekibi tarafından yazılmıştır. Ünlü Nükleer Tıp Profesörü Richard Wahl tarafından kitaba bir önsöz yazılmıştır.
Amazon.com’da kitabın tanıtımı ile ilgili olarak verilen bilgiler aşağıdadır:
“Nuclear Medicine Therapy presents the state of the art in targeted radionuclide therapy, both in clinical practice and contemporary clinical investigation and trials. With contributions from an internationally-distinguished group of physicians and scientists, the book is devoted entirely to the use of nuclear medicine techniques and technology for therapy of malignant and benign diseases. Individual chapters cover the scientific principles and clinical applications of radionuclide therapy and the state of clinical trials of agents currently under investigation in the therapy of tumors involving virtually every organ system. Due to overlapping interest in techniques, indications, and clinical use, the development of radionuclide therapy attracts considerable input from other medical specialists whose collaboration is essential, including radiation and medical oncologists, hematologists, diagnostic radiologists, hepatologists, endocrinologists, and rheumatologists. And because radionuclide therapy is a rapidly evolving field of nuclear medicine, it is the aim of this volume to appeal to all specialists involved in targeted radionuclide therapy and to contribute to the standardization of the practice globally.”
Yukarıdaki kitap tanıtımının orjinaline, aşağıdaki linki tıklayarak ulaşabilirsiniz.
Hardcover: 443 pages
Publisher: Springer, 1st edition, 2013
BU KİTAPLA İLGİLİ OLARAK YAYINLANMIŞ KİTAP ELEŞTİRİLERİ-YORUMLARI:
Prof.Dr.Cumali Aktolun’un bu kitabıyla ilgili olarak Avrupa Nükleer Tıp Dergisi (European Journal of Nuclear Medicine and Molecular Imaging)’nde yayınlanmış Prof.Dr.Luigi Mansi tarafından yazılmış kitap eleştirisi (Book Review) aşağıdadır. Bu yorumun aslına, internetten de aşağıdaki linki tıklayarak ulaşabilirsiniz.
Prof.Luigi Mansi tarafından yazılmış Kitap Yorumunun Türkçe özeti:
‘Bu kitap, nadir bulunacak bir eserdir (latince Nadir Kuş benzetmesi yapılmış). Kitabın başyazarı, Nükleer Tıp alanında 2 tanınmış otorite olan Stanford Üniversitesinden Prof.Dr.Cumali Aktolun ve Cornell Üniversitesinden Prof.Stanley J Goldsmith yapmıştır. Kitabın, önsözünü, John Hopkins Üniversitesinden Richard Wahl yazmıştır. Kitap, 443 sayfa ve 19 bölüm’den oluşmaktadır. Bölümler, homojendir, her biri alanında tanımış Amerikalı, Avrupalı ve Kanadalı yazarlarca yazılmıştır. Bu kitap, Nükleer Tıp branşının geleceği açısından, tedavi tekniklerini öne çıkarması açısıdan, önem taşımaktadır.’
BOOK REVIEWS AND COMMENTS:
Cumali Aktolun and Stanley J. Goldsmith (eds):
Nuclear Medicine Therapy
Springer Science+Business Media, New York, 2013., ISBN: 978-1-4614-4020-8, Luigi Mansi & Mariarosaria Prisco, Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-013-2414-y, published April 12 2013
‘This book is a rara avis (rare bird), being entirely devoted to the principles and clinical applications of radionuclide ther- apy, a fundamental branch of nuclear medicine, which is continually growing in its applications outside its historic territory centred on thyroid diseases. Its growth, in parallel with radionuclide diagnostic imaging, the other main pillar of the “molecular building” constructed with our techniques as the principal material, is in the direction of theranostics, the “portmanteau of therapeutics and diagnostics” (Wikipedia). This book is clear evidence that much of the future is already in the present, the clinical indications for the use of radionu- clide therapy in malignant and benign diseases today being many and effective.
The book is edited by two well-known authorities in nuclear medicine, Cumali Aktolun, at present working at the Stanford University, and Stanley J. Goldsmith, Director of the Division of Nuclear Medicine and Molecular Imaging at Cornell University in New York. They recruited mainly from the USA and Europe, but also from Australia and Canada, some of the major international experts to present the state of the art in targeted radionuclide therapy, both in clinical practice and contemporary clinical investigations and trials.
The book consists of 443 pages organized into three parts, preceded by a preface by the editors and a foreword of Richard Wahl, one of the pioneers of PET in oncology, who is also acknowledged for his contribution in the field of radionuclide therapy, mainly in non-Hodgkin lymphoma. In our opinion, in contrast to the “standard reader’s approach” pushing to fly over the introduction, the reader will find that lingering over these first five pages (VII-XI) is very productive, because they give a very acute and authoritative general view of the field, further allowing a methodological and non-empirical approach to the argument, deeply and extensively analysed in the remaining part of the book.
The first part of the book is the largest, being organized into 16 chapters. They deal with all the most important applications of radionuclide therapy in malignant diseases, including lymphoma, leukaemia, myeloproliferative neoplasms, neuroendocrine tumours, melanomas, brain tumours, differentiated carcinomas of the thyroid, medullary thyroid carcinomas, colorectal cancer, pancreatic adenocar- cinoma, renal cell carcinoma and prostate cancer. Further- more, procedures and techniques regarding the palliation of pain from bone metastases, the local irradiation of the breast using an avidin-biotin targeting system, the therapy of tu- mours and metastases of the liver by intraarterial emboliza- tion using 131I lipiodol or microspheres labelled with 90Y are also reported.
The second part addresses radionuclide therapy in benign diseases and consists of two chapters. The first focuses on metabolic therapy with 131I in hyperthyroid patients affected with Graves-Basedow disease or Plummer’s adenoma, also analysing its role in patients with nontoxic goitre. The second chapter is devoted to radiosynoviorthesis, based on the intraarticular injection of beta-emitting radiocolloids, used in the topical treatment of inflammatory alterations in the synovial membrane that are characteristic of chronic inflammatory arthropathies.
Each chapter of the first two parts is divided into sections that discuss first the general characteristics of the disease to be treated, the radiopharmaceuticals to be used in its treat- ment (also analysing their pharmacokinetics), and clinical applications. Then criteria for selection of patients and rel- ative contraindications to therapy are presented, followed by practical information on patient preparation. To demonstrate the relevance of the content and projection over the next years, future directions are also discussed, including the most important clinical trials. A summary is provided at the end of each chapter, and all chapters are enriched by an extensive and updated bibliography and many by images, schemes and tables.
The third part, consisting of five chapters further divided into several sections, discusses “special topics” in radionuclide therapy including the chemistry of radiopharmaceuticals for therapeutic use, pretargeting, radiobiology as applied to radionuclide therapy (including a very interesting analysis of low dose rate radiation effects), release criteria and other considerations in radiation safety involving radio- nuclide therapy, challenges associated with radionuclide therapy, and the need for interdisciplinary collaboration.
The text is presented as a practical manual, is user friend- ly and, although it is the product of different contributors, may be considered homogeneous in its organization, due to the high level of expertise of the authors and to the efficien- cy of the editorial work.
Describing the state of the art of targeted radionuclide therapy both in clinical practice and in the field of research and clinical trials, this book has to be present in all institu- tions where radionuclide therapy is practised. Its relevance is high because the use of radionuclide therapy is not yet universally standardized even in its original fields of appli- cation, hyperthyroidism and thyroid cancer. Therefore this text, appealing to all specialists interested in radionuclide therapy, warns of the need to standardize the practice and strengthen the role of nuclear medicine in a time when the survival of this discipline as a pure specialty is a matter of discussion. In this direction, a further important field for dissemination, that has to be “politically” stimulated by nuclear medicine departments and scientific societies, is the world of our users. Therapy is an important tool for the integration of nuclear medicine with other medical disciplines, such as endocrinology, oncology, haematology, rheumatology, hepatology, surgery and so on. Being written by leading experts and researchers in the field and also giving a perspective for the near future, the book would be very useful both for practitioners in radionuclide therapy and for residents in nuclear medicine (or radiology). Finally, this book may be suggested to physicists and to all those who have a strong interest in radionuclide therapy.’
3) NUCLEAR ONCOLOGY (Springer, 1999-2000, USA)
Bu kitap, Prof.Dr.Cumali Aktolun’un Amerika Birleşik Devletlerinde yayınlanmış ve tüm dünyada satılan 1. kitabıdır. Kitap, tiroid hastalıkları da dahil Endokrinoloji ve Onkoloji branşlarında Nükleer Tıp teknikleri kullanılarak yapılan tanı ve tedavi yöntemlerini anlatmaktadır. Kitap İngilizce olarak yazılmıştır. Kitabın başyazarları; Prof.Dr.Cumali Aktolun ve USA Pittsburgh Universitesi Tıp Fakültesi Hastanesinden Prof. Newlon Tauxe’tir. Başyazarlığa ilaveten, kitabın, 2 bölümünü Prof.Dr.Cumali Aktolun yazmıştır. Nükleer Tıp branşının öncüsü ünlü Profesör Richard Wagner tarafından kitaba bir önsöz yazılmıştır.
Amazon.com’da kitabın tanıtımı ile ilgili olarak verilen bilgiler aşağıdadır:
“Nuclear Oncology describes the use of radionuclides in the diagnosis and management of malignant tumors. Both in vivo and in vitro techniques are included. The book was written by an international panel of authors, most, if not all, of whom are the pioneers of the techniques described. Their chapters reflect the universal views in the field of nuclear medicine and oncology. Clinical aspects and technical details are presented for both standard and new nuclear oncological techniques, including breast scintigraphy, receptor imaging, monoclonal antibodies and positron emission tomography. This information will therefore be helpful to those dealing with the diagnosis and therapy of cancer using radionuclides, including medical oncologists, radiation oncologists, oncologic surgeons, nuclear medicine physicians and radiologists. Attention is devoted to potential areas of clinical research in nuclear oncology. Therapeutic use of radionuclides is emphasized.”
Hardcover: 456 pages
Publisher: Springer; 1st edition (August 15, 1999)
Product Dimensions: 10.9 x 7.7 x 1.1 inches
BOOK REVIEWS AND COMMENTS:
“…This book would be an important addition to the library of any physician or scientist working in the field of oncology.”
“…This is an important textbook that will help one keep informed about this exciting field….”
“…All chapters written by experts who have researched and published on the subject. Thus the text provides an insight into the past and present status of the field and is laced with personal experiences….”
“The chapters are well written and referenced and contain very helpful tables….”
“Generally the book will be of benefit to the doctors practising in the field of nuclear medicine, who will find it a usefu1 source of reference in difficult times. Certainly it is recommended for trainees in this field. Radiologists and oncologists will also find some pearls in this text.”
“…Being published in 1999, this book is up-to-date, well illustrated and referenced. Most of the chapters have been written by well known people, experienced in the field with relatively little overlap between chapters. There is equal emphasis on the diagnostic and therapeutic aspects of cancer. It is an excellent reference book which will be valuable for all oncologists and radiologists as well as the nuclear medicine fraternity,trained and in training….”